Westpac Banking Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

Westpac Banking Corp’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$734K	Sell	12,997 -12,624	-49%	-$736K	0.05%	232
2025 Q4	$1.52M	Buy	25,621 +20,747	+426%	+$1.13M	0.1%	181
2025 Q3	$264K	Sell	4,874 -9,106	-65%	-$521K	0.02%	315
2025 Q2	$768K	Buy	+13,980	New	+$823K	0.05%	231
2025 Q1	–	Sell	-3,501	Closed	-$230K	–	470
2024 Q4	$230K	Buy	3,501 +1,414	+68%	+$94.7K	0.02%	350
2024 Q3	$147K	Hold	2,087	–	–	0.01%	404
2024 Q2	$172K	Hold	2,087	–	–	0.01%	339
2024 Q1	$182K	Hold	2,087	–	–	0.01%	356
2023 Q4	$201K	Buy	2,087 +735	+54%	+$65K	0.02%	338
2023 Q3	$120K	Hold	1,352	–	–	0.01%	431
2023 Q2	$117K	Sell	1,352 -16,102	-92%	-$1.52M	0.01%	409
2023 Q1	$1.7M	Buy	17,454 +3,923	+29%	+$407K	0.02%	551
2022 Q4	$1.4M	Buy	13,531 +355	+3%	+$33.3K	0.02%	552
2022 Q3	$1.12M	Hold	13,176	–	–	0.02%	600
2022 Q2	$1.09M	Hold	13,176	–	–	0.01%	652
2022 Q1	$1.02M	Hold	13,176	–	–	0.01%	689
2021 Q4	$1.16M	Buy	13,176 +997	+8%	+$82.3K	0.01%	668
2021 Q3	$941K	Hold	12,179	–	–	0.01%	734
2021 Q2	$1.02M	Hold	12,179	–	–	0.01%	750
2021 Q1	$920K	Hold	12,179	–	–	0.01%	706
2020 Q4	$1.07M	Hold	12,179	–	–	0.01%	714
2020 Q3	$927K	Hold	12,179	–	–	0.01%	677
2020 Q2	$1.5M	Hold	12,179	–	–	0.02%	561
2020 Q1	$1.03M	Hold	12,179	–	–	0.02%	582
2019 Q4	$1.03M	Hold	12,179	–	–	0.01%	676
2019 Q3	$821K	Hold	12,179	–	–	0.01%	692
2019 Q2	$1.04M	Hold	12,179	–	–	0.02%	546
2019 Q1	$1.08M	Hold	12,179	–	–	0.02%	531
2018 Q4	$1.04M	Buy	12,179 +2,161	+22%	+$206K	0.02%	571
2018 Q3	$971K	Hold	10,018	–	–	0.02%	545
2018 Q2	$944K	Hold	10,018	–	–	0.02%	508
2018 Q1	$812K	Hold	10,018	–	–	0.02%	532
2017 Q4	$893K	Hold	10,018	–	–	0.02%	485
2017 Q3	$932K	Hold	10,018	–	–	0.02%	518
2017 Q2	$910K	Sell	10,018 -3,281	-25%	-$298K	0.02%	525
2017 Q1	$1.17M	Sell	13,299 -6	-0%	-$534	0.01%	615
2016 Q4	$1.11M	Buy	13,305 +499	+4%	+$42.9K	0.01%	556
2016 Q3	$1.18M	Buy	12,806 +3,879	+43%	+$365K	0.01%	528
2016 Q2	$695K	Buy	8,927 +2,050	+30%	+$174K	0.01%	663
2016 Q1	$567K	Sell	6,877 -2,633	-28%	-$214K	0.01%	650
2015 Q4	$996K	Sell	9,510 -42,667	-82%	-$4.46M	0.01%	573
2015 Q3	$5.5M	Sell	52,177 -46,684	-47%	-$6.24M	0.06%	298
2015 Q2	$13.5M	Buy	98,861 +84,993	+613%	+$10.5M	0.13%	149
2015 Q1	$1.87M	Sell	13,868 -1,550	-10%	-$164K	0.02%	516
2014 Q4	$1.39M	Buy	15,418 +434	+3%	+$36.1K	0.01%	556
2014 Q3	$1.08M	Buy	14,984 +5,399	+56%	+$355K	0.01%	600
2014 Q2	$596K	Sell	9,585 -140	-1%	-$8.46K	0.01%	709
2014 Q1	$663K	Buy	9,725 +1,100	+13%	+$81.1K	0.01%	654
2013 Q4	$606K	Buy	8,625 +181	+2%	+$12.3K	0.01%	703
2013 Q3	$610K	Buy	8,444 +2,544	+43%	+$169K	0.01%	678
2013 Q2	$329K	Buy	+5,900	New	+$368K	0.01%	813

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Westpac Banking Corp's BMRN Position: Q1 2026 in Review

Westpac Banking Corp reduced its BioMarin Pharmaceuticals (BMRN) stake by 49% in Q1 2026, selling an estimated $736K and leaving 12,997 shares worth $734K. The position accounts for 0.05% of the portfolio, ranked #232.

Westpac Banking Corp first reported a position in BMRN in Q2 2013 and has held it in 51 quarters since. The position peaked at $13.5M in Q2 2015. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Westpac Banking Corp held 12,997 shares of BioMarin Pharmaceuticals worth $734K as of Q1 2026.
Westpac Banking Corp sold 12,624 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $736K.
BioMarin Pharmaceuticals made up 0.05% of Westpac Banking Corp's portfolio in Q1 2026, its #232 holding.
Westpac Banking Corp first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
Westpac Banking Corp's BioMarin Pharmaceuticals position peaked at $13.5M in Q2 2015.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Westpac Banking Corp's 13F filing for Q1 2026, filed 12 May 2026.